Chris Eso, formerly VP of M&A and portfolio manager at Medtronic, will lead the medical device group’s corporate venture capital initiatives.
US medical device producer Medtronic has named Chris Eso vice president and global head of corporate and business development, mergers and acquisitions, and ventures.
Eso joined Medtronic in 2011 and assumed a series of roles in business and corporate development as well as strategy and growth. Most recently, he spent a year as VP of M&A and managed the firm’s cardiovascular portfolio.
Founded in 1949, Medtronic provides devices and therapies targeting chronic diseases such as heart failure, Parkinson’s disease, urinary incontinence, Down syndrome, obesity and diabetes. It conducted corporate venturing under VP of venture capital David Neustaedter until his departure in September 2022.
Medtronic did not disclose new investments until March 2023 when it participated in remote heart monitor provider Fire1’s $25m funding round. Last month, the firm chipped into wearable nerve stimulation system developer Avation Medical’s $22m series C round.
